Accelerating the scale-up of biopharmaceutical production is essential for bringing new therapies to market more quickly and cost-effectively. Predicting cell growth accurately at scale, based on data from laboratory and pilot studies, is a complex task. This complexity is compounded by the need to integrate data from various sources. Streamlining this scale-up process can significantly reduce development times and costs, ultimately speeding up the delivery of innovative biopharmaceuticals to patients.
